An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2019
Price : $35 *
At a glance
- Drugs Dezamizumab (Primary) ; Miridesap (Primary) ; Miridesap (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- Sponsors GlaxoSmithKline
- 10 Dec 2018 Status changed from suspended to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 20 Aug 2018 Status changed from recruiting to suspended.